Denileukin Diftitox (Ontak) as Maintenance Therapy for Peripheral T-Cell Lymphomas: Three Cases with Sustained Remission
about
Targeted delivery of an ADP-ribosylating bacterial toxin into cancer cells.Primary cutaneous anaplastic large-cell lymphoma: Complete remission for 13 years after denileukin diftitox.Progress in Nanomedicine: Approved and Investigational Nanodrugs.STAT5 inhibition induces TRAIL/DR4 dependent apoptosis in peripheral T-cell lymphoma.
P2860
Denileukin Diftitox (Ontak) as Maintenance Therapy for Peripheral T-Cell Lymphomas: Three Cases with Sustained Remission
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Denileukin Diftitox (Ontak) as ...... Cases with Sustained Remission
@ast
Denileukin Diftitox (Ontak) as ...... Cases with Sustained Remission
@en
type
label
Denileukin Diftitox (Ontak) as ...... Cases with Sustained Remission
@ast
Denileukin Diftitox (Ontak) as ...... Cases with Sustained Remission
@en
prefLabel
Denileukin Diftitox (Ontak) as ...... Cases with Sustained Remission
@ast
Denileukin Diftitox (Ontak) as ...... Cases with Sustained Remission
@en
P2093
P2860
P356
P1476
Denileukin Diftitox (Ontak) as ...... Cases with Sustained Remission
@en
P2093
Alejandra C Fuentes
Cathy D Spears
Ellen Szwed
Long H Dang
Nam H Dang
Sandeep Thaper
P2860
P304
P356
10.1155/2015/123756
P577
2015-07-09T00:00:00Z